Genomics

Dataset Information

0

The landscape of therapeutic vulnerabilities in EGFR inhibitor osimertinib drug tolerant persister cells [ATAC-seq]


ABSTRACT: Third-generation EGFR tyrosine kinase inhibitors (EGFR-TKIs), including osimertinib, an irreversible EGFR-TKI, are important treatments for non-small cell lung cancer with EGFR-TKI sensitizing or EGFR T790M resistance mutations. Whilst patients treated with osimertinib show clinical benefit, disease progression and drug resistance are common. Emergence of de novo acquired resistance from a drug tolerant persister (DTP) cell population is one mechanism proposed to explain progression on osimertinib and other targeted cancer therapies. Here we profiled osimertinib DTPs using RNA-seq, ChIP-seq, and ATAC-seq to characterize the features of these cells and performed drug screens to identify therapeutic opportunities.

ORGANISM(S): Homo sapiens

PROVIDER: GSE193256 | GEO | 2022/04/06

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

2022-04-06 | GSE193257 | GEO
2022-04-06 | GSE193258 | GEO
2022-04-28 | GSE201608 | GEO
2024-03-30 | GSE262582 | GEO
2020-06-25 | GSE153183 | GEO
2021-03-11 | PXD020108 | Pride
2021-08-27 | GSE168280 | GEO
2024-01-22 | GSE253478 | GEO
2021-12-31 | GSE155341 | GEO
2023-01-09 | PXD034037 | Pride